We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Porsolt & Metris Sign a Co-Marketing Agreement
News

Porsolt & Metris Sign a Co-Marketing Agreement

Porsolt & Metris Sign a Co-Marketing Agreement
News

Porsolt & Metris Sign a Co-Marketing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Porsolt & Metris Sign a Co-Marketing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Porsolt and Partners Pharmacology (Porsolt) and Metris have announced that they have entered into a global co-marketing agreement to promote preclinical screening services using Laboras , a non-invasive technology for automatic and comprehensive in vivo behavioral characterization of drug candidates.

Under this alliance, Porsolt will offer CRO services utilizing the in vivo screening platform to its clients. The Laboras system enables the measurement of multiple behavioral pharmacodynamic endpoints in a single experiment utilizing a high throughput non-invasive system.

Dr. Martine Lemaire, Senior Director - Commercial & Business Development of Porsolt said, “We are thrilled by the synergy between Porsolt’s long-established and recognized expertise in behavioral pharmacology and the high-quality, proven utility of the Laboras innovative technology system.

This partnership has formed in response to the needs expressed by Porsolt’s clients for increased information on drug-like molecules earlier in the drug discovery process. It fits obviously with our strategy to constantly deliver superior quality scientific solutions tailored to our customer’s need.”
Advertisement